drugset
drugset / Trial / NCT04550195

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants

NCT04550195 ↗

Phase 1 Completed 26 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986337 in healthy participants and in healthy Japanese participants.

Timeline

Start
2020-09-17
Primary completion
2021-03-03
Completion
2021-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986337 Unknown — Oral
Background Famotidine Other / unclassified — —

Indications

No indication recorded.